{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:11:51Z","timestamp":1772136711987,"version":"3.50.1"},"reference-count":16,"publisher":"ALUNA","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"abstract":"<jats:p>Demyelinating diseases of the central nervous system constitute a heterogeneous group of diseases. The best known is multiple sclerosis, while neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare diseases. A 19-year-old female patient was admitted to the neurology department due to rapidly progressing memory and speech disorders. Mild mixed aphasia and right-sided pyramidal syndrome were diagnosed. Magnetic resonance imaging (MRI) of the brain revealed acute nodular demyelination in the left hemisphere. Intravenous methylprednisolone was administered. After approximately 2 months, the patient was readmitted due to several generalized epileptic seizures. At that time, the patient was transferred to a clinical center, where extensive diagnostics was performed. Among others, acute disseminated encephalitis, autoimmune encephalitis, tumefactive multiple sclerosis, and tumor were taken into consideration. MRI with spectroscopy and angiography revealed degenerative changes following acute demyelination. General examination of the cerebrospinal fluid was normal. No anti-neuronal antibodies were detected. However, positive anti-MOG antibodies were detected (and antibodies against aquaporin 4 were negative), which led to a suspicion of MOGAD. The patient was discharged home with a recommendation to use antiepileptic drugs and oral steroids. It is important to remember about rare demyelinating diseases, such as MOGAD, which require differentiation from multiple sclerosis. The prognosis for this condition is generally better, but the disease can lead to permanent neurological damage.<\/jats:p>","DOI":"10.36740\/merkur202601111","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:37:56Z","timestamp":1772134676000},"page":"73","source":"Crossref","is-referenced-by-count":0,"title":["Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge \u2013 based on the case of a young woman with MOGAD"],"prefix":"10.36740","volume":"54","author":[{"given":"Mateusz","family":"Roszak","sequence":"first","affiliation":[{"name":"STUDENT SCIENTIFIC ASSOCIATION AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Nosal","sequence":"additional","affiliation":[{"name":"STUDENT SCIENTIFIC ASSOCIATION AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Sadowski","sequence":"additional","affiliation":[{"name":"STUDENT SCIENTIFIC ASSOCIATION AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Sierakowska","sequence":"additional","affiliation":[{"name":"STUDENT SCIENTIFIC ASSOCIATION AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kandziora","sequence":"additional","affiliation":[{"name":"HELIMED Diagnostic Imaging Center, St. Jadwiga Provincial Specialist Hospital in Opole, Opole, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"\u0141abuz-Roszak","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Jeyakumar N, Lerch M, Dale RC, Ramanathan S. MOG antibody-associated optic neuritis. Eye (Lond). 2024; 38(12): 2289-2301. doi: 10.1038\/s41433-024-03108-y.","DOI":"10.1038\/s41433-024-03108-y"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Sechi E, Krecke KN, Pittock SJ. Frequency and characteristics of MRI abnormalities in patients with myelin oligodendrocyte glycoprotein antibodies. Multiple Scler. 2021;27(13):2055-2066. doi: 10.1177\/1352458520907900.","DOI":"10.1177\/1352458520907900"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Alzarooni H, Inshasi J, Alawadhi A, Giacomini P. MOGAD and NMOSD: insights on patients\u2019 radiological and laboratory findings from a single UAE center. Front Neurol. 2024;15:1480723. doi: 10.3389\/fneur.2024.1480723.","DOI":"10.3389\/fneur.2024.1480723"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Y\u0131lmaz U. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children. Explor Neuroprotect Ther. 2024;4:38-54. doi.org\/10.37349\/ent.2024.00069.","DOI":"10.37349\/ent.2024.00069"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Kim KH, Kim W, Kim SH, et al. Clinical and radiological features of myelin oligodendrocyte glycoprotein antibody-associated myelitis with a particular focus on adult patients. J Clin Neurol. 2022;18(3):280-289. doi: 10.3988\/jcn.2022.18.3.280.","DOI":"10.3988\/jcn.2022.18.3.280"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Zhou Y, Jia X, Yang H, Chen C, Sun X, Peng L, Kermode AG, Qiu W. Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes. Eur J Neurol. 2019;26(1):175-183. doi: 10.1111\/ene.13791.","DOI":"10.1111\/ene.13791"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358. doi: 10.3389\/fneur.2023.1260358.","DOI":"10.3389\/fneur.2023.1260358"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Seok JM, Jeon M, Chung YH, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to the epitope reactivity. Front Neurol. 2023;14:1200961. doi: 10.3389\/fneur.2023.1200961.","DOI":"10.3389\/fneur.2023.1200961"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Valencia-Sanchez C, Aksamit AJ, Guo Y, et al. Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2023;93(2):297-302. doi: 10.1002\/ana.26549.","DOI":"10.1002\/ana.26549"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Goh Y, Lye PP, Tambyah PA, et al. Case Report: MOGAD \u2013 a steroid-responsive autoimmune meningoencephalitis mimicking infection. Front Immunol. 2025;16:1516178. doi.org\/10.3389\/fimmu.2025.1516178.","DOI":"10.3389\/fimmu.2025.1516178"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Cacciaguerra L, Flanagan EP, Ramanathan S, et al. Tumefactive demyelination in MOG Ab-associated disease. Neurology. 2023;100(17):e1711-e1723. doi: 10.1212\/WNL.0000000000206820.","DOI":"10.1212\/WNL.0000000000206820"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Yang JX, Chen SD, He WB, et al. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) with coexisting anti-NMDAR encephalitis: a case report and systematic review. Mult Scler Relat Disord. 2023;73:104669. doi: 10.3389\/fimmu.2023.1149987.","DOI":"10.3389\/fimmu.2023.1149987"},{"key":"ref12","unstructured":"13. Cleveland Clinic Mellen Center. Myelin Oligodendrocyte Antibody Disease \u2013 Fact Sheet. 2022. https:\/\/my.clevelandclinic.org\/departments\/neurological\/depts\/multiple-sclerosis\/ms-approaches\/myelin-oligodendrocyte-glycoprotein-antibody-disease (Access: October 2025)"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Montalvo M, Matera E, Yeaman MR, et al. Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease. Epilepsia. 2022;63(12):3180-3191. doi: 10.1111\/epi.17424.","DOI":"10.1111\/epi.17424"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. doi: 10.1016\/j.msard.2020.102251.","DOI":"10.1016\/j.msard.2020.102251"},{"key":"ref15","unstructured":"16. Written informed consent was obtained from the patient for publication of this case report and accompanying images"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:38:01Z","timestamp":1772134681000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek20026i1net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,2,15]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202601111","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}